Two things I took away from the conf call:
1) Ovarian: "Additionally, 52% of the patient had tumors and had failed respond to prior anti-angiogenic agents including Avastin. Practically, most patients in Phase II trials has a better prognosis making this already a late trial. So while we design the trial primarily to look at safety, we were happy to see such significant efficacy."
2) RGBM: "We are saying that we are according to plan, but actually we are ahead of plan, but wanted to be very careful, because it goes month-by-month, but right now the excitement around the trial is quite big and we are recruiting very well."
News 
Market Data 
Discover 
